ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.

Benzinga • Dec 12, 2025

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This recommendation will help facilitate early access to medicines that address c.

Business Wire • Dec 12, 2025

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

ImmunityBio delivered strong 3Q25 results, with Anktiva driving 434% YoY product revenue growth and a narrowed operating loss. IBRX's cash position improved to $257.8 million, providing a 3-4 quarter runway, though net debt remains high at $603 million. The company's robust adoption underpins current valuation; future growth hinges on expanding indications and successful clinical trial readouts.

Seeking Alpha • Dec 3, 2025

A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know

Bought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value This new position ranks as the fund's 2nd-largest holding, representing 4.4% of AUM

The Motley Fool • Nov 19, 2025

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

ImmunityBio shows strong commercial momentum with ANKTIVA, reporting significant revenue growth and improved net loss in Q3. IBRX pipeline progress includes promising data in glioblastoma, NSCLC, non-Hodgkin lymphoma, and a new Phase II trial for long COVID. Despite bullish long-term outlook, near-term risks include ongoing losses, potential dilution, regulatory hurdles, and manufacturing dependencies.

Seeking Alpha • Nov 19, 2025

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical treatment conversations. Fewer than one in five patients surveyed (18%) report their healthcare providers (HCPs) discuss all available treatment options during most or every visit. More than four in five (84%) believe immunotherapy has fewer side effects than ch.

Business Wire • Nov 13, 2025

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025. In the third quarter of 2025, ImmunityBio reported $31.8 million of product revenue, representing a 434% increase from $6.0 million in the third quarter of 2024. This growth reflects continued commercial traction of ANKTIVA in combination with BCG in BCG-unresponsive NMIBC with CIS with or.

Business Wire • Nov 5, 2025

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.

Benzinga • Oct 22, 2025

ImmunityBio: A Small Bet Is Warranted

ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK program and expanding pipeline support the investment thesis for IBRX.

Seeking Alpha • Oct 3, 2025

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.

MarketBeat • Sep 17, 2025